The FDA Granted Orphan Drug Designation to Regenxbio Investigational Gene Therapy Drug RGX-202 for Duchenne Muscular Dystrophy

Regenxbio Granted Orphan Drug Designation for RGX-202
Regenxbio (RGNX) announced the U.S. FDA granted Orphan Drug Designation for RGX-202 - a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy.

RGX-202 is designed to deliver a novel, optimized microdystrophin transgene with a unique C-terminal domain and a . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.